R Broadbent — Page 2 | PubMed Health

PubMed1983

Reproducibility of expired breath hydrogen levels in the neonate: a comparison of two methods for sample collection.

We have compared a nasopharyngeal catheter method for breath sampling and a valved collection device. Sample quality was assessed by simultaneous oxygen measurement and reproducibility was checked by the analysis of 50 pairs of samples from four premature neonates. Both collection methods produced samples of highly variable quality suggesting a variable mixture of alveolar and non-alveolar air as well as differences in expired oxygen levels between babies. The mean oxygen levels were similar for both sampling techniques. Linear regression analysis of paired hydrogen results showed a highly significant correlation coefficient r = 0.73. This was improved markedly to r = 0.94 by normalization of hydrogen values based on observed oxygen levels, and so supports the earlier article by Robb and Davidson [1]. All breath hydrogen analyses require a measure of sample quality. Reproducible results and meaningful changes in hydrogen concentration in breath samples can only be achieved by correction according to sample quality. Correction to a common oxygen value should allow quantitative comparisons between patients. Samples were best collected from neonates by the nasopharyngeal catheter method, which least disturbed the patient, allowed multiple sample collection and gave lower oxygen and higher hydrogen values where large differences between pairs occurred.

Autoanalysis↗

PubMedDate not supplied

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.

The mucin MUC1 is greatly increased in breast cancer and is a potential target for immunotherapy. In mice, MUCI conjugated to oxidized mannan (MUC1-mannan fusion protein [M-FP]) targets the mannose receptor and induces a high frequency of cytotoxic T lymphocytes and anti-tumor responses. On this basis, three phase I trials were performed in patients with adenocarcinoma to evaluate the toxicity and the immunologic responses to mannan MUCI. Forty-one patients with metastatic or locally advanced carcinoma of the breast (trial 1), colon (trial 2), and various adenocarcinomas (trial 3) received increasing doses of M-FP (1 to 300 microg). The immunizations were given at weekly intervals (weeks 1 to 3) and repeated in weeks 7 to 9. Cyclophosphamide (to increase cellular immunity) was given on weeks 1 and 4. M-FP was given intramuscularly in trial 1 and intraperitoneally in trial 2. No toxic effects occurred, and delayed-type hypersensitivity responses were present only as a microscopic lymphocytic infiltration. Overall, approximately 60% of the patients had high-titer MUC1 immunoglobulin G1 antibody responses, with the intraperitoneal route yielding approximately 10-fold higher responses. Cellular responses (proliferation, cytotoxic T cells, or CD8 T cells secreting tumor necrosis factor-alpha alphand interferon-gamma in response to MUC1 stimulation in vitro) were found in 28% of the patients, which was similar to that seen without cyclophosphamide. In most patients, disease progressed, but in five it remained stable. In addition, there were no objective responses. M-FP is not toxic and induces immune responses that were amplified by the intraperitoneal route of immunization. Cyclophosphamide was of no benefit.

Adenocarcinoma↗